CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2461
-0.0038 (-1.53%)
At close: Mar 2, 2026
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
320.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | - | - | - |
| May 31, 2024 | - | - | - |
| May 31, 2023 | - | - | - |
| May 31, 2022 | 266.00K | - | - |
| May 31, 2021 | - | - | - |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Harvard Apparatus Regenerative Technology | 743.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
CytoDyn News
- 10 days ago - CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference - GlobeNewsWire
- 4 weeks ago - CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer - GlobeNewsWire
- 2 months ago - December 2025 Letter to Shareholders - GlobeNewsWire
- 3 months ago - CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 3 months ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 months ago - CytoDyn Secures $30 Million Commitment from Yorkville Advisors - GlobeNewsWire
- 4 months ago - Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 5 months ago - CytoDyn to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire